Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SYNTEX SALES GROWTH FROM 1994-2002 ESTIMATED AT 7%-9.5%

This article was originally published in The Tan Sheet

Executive Summary

SYNTEX SALES GROWTH FROM 1994-2002 ESTIMATED AT 7%-9.5% per year in tender offer documents sent to Syntex shareholders as part of Roche's proposed acquisition of the company. Projections for Syntex discussed with Roche during merger negotiations "reflected sales and net income increasing at compound average annual growth rates of approximately 7% and 17.4%" in the "base case" between 1994 and 2002. In the "upside case," Syntex forecast 9.5% sales growth and 22.1% earnings growth. Both estimates were made "on a stand-alone basis and without reflecting any synergies for the acquisition of the company" by Roche, the May 6 tender offer documents state.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel